Mar 05th 2013 - Edison Investment Research today published a report on Circadian Technologies entitled "Divine Prospects". In summary, the report says:
Circadian has reorganised into three subsidiary operating companies: Ceres Oncology, Opthea and Precision Diagnostics, each of which could attract private funding. The Ceres investment case is the potential of VGX-100 (completing Phase I) to reduce secondary lymphoedema, a side effect of major breast cancer surgery. This may start Phase II in Q413. The major market is the potential of VGX-100 in combination with Avastin in solid tumours. This requires a partnering deal, assumed in 2014. Opthea is developing VGX-300 (preclinical), which may be used in combination with Lucentis or Eylea in wet AMD. Precision is developing a speciality diagnostic business. The Imclone-partnered IMC-3C5 could produce Phase I data in H213.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »